The Australian Therapeutic Goods Administration has given Pfizer Inc. the go-ahead to apply for provisional registration of two adapted versions of the Pfizer/BioNTech COVID-19 vaccine, Cominarty (tozinameran), targeted at the Omicron variant.
The two products are a monovalent vaccine, riltozinameran (Comirnaty Omicron), and a bivalent vaccine combining riltozinameran with tozinameran (Comirnaty Bivalent).